NVCR Novocure Ltd
Novocure Ltd price
-1.52% Past Week
Market Cap
1.75B
Day’s Range
52W Range
Volume (3M)
1.06M
Price-Earnings Ratio
-11.61
Revenue
577.74M
Set price alert
Set price alert
Price alerts notify you when an asset hits a target you set.
Novocure Ltd Latest News
About Novocure Ltd
Novocure Ltd is a biopharmaceutical oncology-focused company engaged in the development and commercialisation of a novel cancer treatment that targets solid tumours, known as Tumour Treating Fields or TTFields. This treatment focuses on the disruption of cancer cell division through the use of alternating electric fields applied at specific frequencies. The firm has its corporate headquarters in Saint Helier in Jersey, with offices in the US, Switzerland, Tokyo, and Haifa. The firm was founded in 2000.
Novocure Ltd has brought two FDA approved products to market that use TTFields to treat both newly diagnosed and recurrent glioblastoma. Products in the pipeline are being developed with the aim of treating patients with brain metastasis, non-small cell lung cancer, ovarian cancer, mesothelioma, liver cancer, gastric cancer, and traditionally hard-to-treat pancreatic cancer.
TTFields therapy is delivered through a portable medical device, and the treatment is designed to enable patients to receive continuous cancer treatment with minimal disruption to their daily lives and activities. The firm is listed on the NASDAQ, where it trades under the stock ticker NVCR.
You can add this company to your watchlist here on eToro to get regular news and instant updates on changes to the NVCR price chart.
Show MoreCEO
Asaf Danziger
Employees
1.4K
Founded
2000
HQ
GB
Did you know? Novocure Ltd's device, Optune, uses electric fields to disrupt cancer cells, offering a non-invasive treatment for brain tumors.
Top Discussions
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
55
High
Industry
Avg. 50
40
Environment
67
Social
47
Governance
Consensus
Moderate Buy
Price Target
35.00
People Also Bought
- SAGE Sage Therapeutics Inc -0.49%
- DVAX Dynavax Technologies Corp -0.59%
- OPK OPKO Health Inc 0%
- QURE uniQure NV 2.45%
- KLTR Kaltura Inc. 3.94%